How Amicus Therapeutics Is Revolutionizing the Treatment of Rare Conditions
For a long time, patients have been suffering from some devastating rare diseases. The existing research on these diseases has not been sufficient. To end the suffering of such patients, Amicus Therapeutics seeks to advance research in relation to such diseases. Indeed, Amicus Therapeutics is one of the leading biotechnology companies across the globe. The company aims to develop a cure for various diseases relating to human genetics. For instance, the company has played a significant role in the development of migalastat.
Migalastat is a revolutionary method of treating Fabry disease that has a devastating effect on many patients. Indeed, the development of the cure is in last stage and is just about to be rolled out by the company. Amicus therapeutics has a team of professionals who are willing to spearhead research. According to the website of the company, most of the scientists are driven by the desire to enhance the life of their patients. It is the passion of such scientists that has made it possible for them to cover a lot of ground within a short period of time.
In seeking treatment for the rare conditions, the company has adopted a bold approach that has not been experimented before. It is important to note that the company is mainly based in Cranbury, New Jersey. For quite some time, the company has been trading on the NASDAQ (http://alivenewspaper.com/2017/09/amicus-therapeutics-fabry-disease-treatment/). Amicus Therapeutics has been working hard to work on conditions generally referred to as the lysosomal storage disorders. Currently, the company has many treatments in the pipeline. As noted earlier, migalastat is one of the major treatments that the company has been embarking on. The company has also been developing treatments for the treatment of the Pompe disease.
The technological advancements that the company has been leveraging on have made it easier for it to develop cutting edge approaches to treating diseases. The leadership of Amicus Therapeutics has played a significant role in helping the development of innovative treatments. For instance, the chairman of the company, John Crowley, is totally involved in the development of treatments for the rare diseases. His inspiration to find treatment for such conditions stems from the diagnosis of his children with Pompe disease in 1998 (ForexWizard).